Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades Humanigen to Neutral

HC Wainwright & Co. Downgrades Humanigen to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Humanigen (NASDAQ:HGEN) from Buy to Neutral.

byBenzinga Newsdesk

July 13, 2022

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis downgrades Humanigen (NASDAQ:HGEN) from Buy to Neutral.

SEC To Delay Approval Of Spot Ethereum ETFs, TD Cowen Forecasts

By Mehab Qureshi

January 15, 1:18 AM

The Securities and Exchange Commission is predicted to delay the approval of spot Ethereum (CRYPTO: ETH) exchange-traded funds (ETFs), according to investment bank TD Cowen.

BTC

P/E Ratio Insights for GE HealthCare Techs

By Benzinga Insights

April 11, 1:00 PM

In the current market session, GE HealthCare Techs Inc. (NASDAQ:GEHC) stock price is at $80.08, after a 0.64%…

GEHC

Coty Renews License Agreement With Adidas

By Shivani Kumaresan

August 18, 5:50 AM

Beauty products company Coty Inc (NYSE: COTY) has renewed its long-term license agreement with Adidas AG (OTC: ADDYY).

ADDYY

FDA Strikes Out Amneal Pharmaceuticals’ Parkinson’s Disease Candidate, Stock Falls

By Vandana Singh

July 5, 7:42 AM

Amneal Pharmaceuticals Inc (NYSE: AMRX) received an FDA Complete Response Letter (CRL) regarding its New Drug Application for IPX203

AMRX

HC Wainwright & Co. Downgrades Humanigen to Neutral

Related Posts

SEC To Delay Approval Of Spot Ethereum ETFs, TD Cowen Forecasts

P/E Ratio Insights for GE HealthCare Techs

Coty Renews License Agreement With Adidas

FDA Strikes Out Amneal Pharmaceuticals’ Parkinson’s Disease Candidate, Stock Falls